

[Skip to Main Content](#)

## Login to your account

Email/Username

Password

[Show](#)

[Forgot password?](#)

☒ Remember me

Don't have an account?

[Create a Free Account](#)

If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password

Email\*

If the address matches a valid account an email will be sent to \_\_email\_\_ with instructions for resetting your password

[Cancel](#)

 Advertisement

 [Lung Cancer](#)

[Close](#)

- [Home](#)
- [Articles and Issues](#)
  - [Back](#)
  - [Articles in Press](#)
  - [Current Issue](#)
  - [List of Issues](#)
- [For Authors](#)
  - [Back](#)
  - [About Open Access](#)
  - [Author Information](#)
  - [Permissions](#)
  - [Researcher Academy](#)
  - [Submit a Manuscript](#)
- [Journal Info](#)
  - [Back](#)
  - [About Open Access](#)
  - [About the Journal](#)
  - [Abstracting/Indexing](#)
  - [Advertising Information](#)
  - [Career Opportunities](#)
  - [Contact Information](#)
  - [Editorial Board](#)
  - [Pricing](#)
  - [New Content Alerts](#)
- [Subscribe](#)

- [Society Info](#)
  - [Back](#)
  - [International Lung Cancer Consortium \(ILCCO\)](#)
  - [European Thoracic Oncology Platform \(ETOP\)](#)
  - [British Thoracic Oncology Group \(BTOG\)](#)
- [More Periodicals](#)
  - [Back](#)
  - [Find a Periodical](#)
  - [Go to Product Catalog](#)

Search for...

Go search

All Content



[Advanced Search](#)[Save search](#)

Please enter a term before submitting your search.

[Ok](#)

- [Submit Article](#)
- [Log in](#)
- [Register](#)
- [Log in](#)
  - [Submit Article](#)
  - [Log in](#)
- [Subscribe](#)
- [Claim](#)

Full length article| [Volume 73, ISSUE 3](#), P302-309, September 01, 2011

- [Purchase](#)
  - [Academic and Personal](#)
  - [Corporate R&D Professionals](#)
- [Subscribe](#)
- [Save](#)
  - [Add To Online Library](#) Powered By Mendeley
  - [Add To My Reading List](#)
  - [Export Citation](#)
  - [Create Citation Alert](#)
- [Share](#)

Share on

  - Email
  - Twitter
  - Facebook
  - Linked In
  - Sina Weibo
- [more](#)
  - [Reprints](#)
  - [Request](#)
- [Top](#)

**Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells**

- [Hakan Akca](#)  
Hakan Akca  
Correspondence  
Corresponding author. Tel.: +90 258 296 2517; fax: +90 258 296 2433.  
  - 
  -
Affiliations  
Medical Biology Department, School of Medicine, Pamukkale University, Kinikli, Denizli, Turkey  
[Search for articles by this author](#)
- [Aydin Demiray](#)  
Aydin Demiray  
Affiliations  
Medical Biology Department, School of Medicine, Pamukkale University, Kinikli, Denizli, Turkey  
[Search for articles by this author](#)
- [Onur Tokgun](#)  
Onur Tokgun  
Affiliations  
Medical Biology Department, School of Medicine, Pamukkale University, Kinikli, Denizli, Turkey  
[Search for articles by this author](#)
- [Jun Yokota](#)  
Jun Yokota  
Affiliations  
Biology Division, National Cancer Center Research Institute, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan  
[Search for articles by this author](#)

Published: February 21, 2011 DOI: <https://doi.org/10.1016/j.lungcan.2011.01.012>

[Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFkB pathway in lung cancer cells](#)

[Previous Article Regulation of VEGF-expression by patupilone and ionizing radiation in lung adenocarcinoma cells](#)

[Next Article EUS-FNA for the detection of left adrenal metastasis in patients with lung cancer](#)



 Advertisement

## Abstract

PTEN is inactivated in a subset of lung cancer; therefore, we investigated the involvement of PTEN inactivation in invasiveness of lung cancer cells. AKT at Ser473 was phosphorylated in several lung cancer cell lines with loss of PTEN expression. Therefore, we created a tetracycline inducible expression system of wild-type PTEN (PTEN-WT) as well as catalytically (PTEN-G129R) and lipid phosphatase (PTEN-G129E) inactive PTEN mutants using the PC14, PC9 and PC3 lung adenocarcinoma cell lines, in which endogenous PTEN expression was not detected and AKT at Ser473 was phosphorylated by Western blot analysis. Induction of PTEN-WT reduced phosphorylation of AKT and inhibited the transcriptional activity of NFkB, whereas PTEN mutants did not, suggesting that PTEN inactivation results in the activation of the AKT/NFkB pathway in PC14, PC9 and PC3 cells. Furthermore, overexpression of PTEN-WT suppressed anchorage independent growth in soft agar and reduced invasiveness in a trans-well chamber assay of PC14 cells. Neither PTEN-G129R nor PTEN-G129E had suppressive effects on anchorage independent growth and invasiveness. Augmentation of invasiveness by constitutively active AKT was also shown in mouse NIH3T3 cells. Therefore, it was strongly indicated that activation of the PI3K/AKT/NFkB pathway by PTEN inactivation results in augmented invasiveness in lung cancer cells and lipid phosphatase activity of PTEN plays a key role in this process.

## Keywords

- [PTEN](#)
- [AKT](#)
- [NFkB](#)
- [Invasion](#)
- [Lung cancer](#)
- [Gene cloning](#)

To read this article in full you will need to make a payment

### Purchase one-time access:

[Academic and PersonalCorporate R&D Professionals](#)

- One-time access price info

### Subscribe:

[Subscribe to \*Lung Cancer\*](#)

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

## References

1.
  - Wang S.I.
  - Puc J.
  - Li J.
  - Bruce J.N.
  - Cairns P.
  - Sidransky D.

Somatic mutations of PTEN in glioblastoma multiforme.  
*Cancer Res.* 1997; 19: 4183-4186

[View in Article](#)

- [Google Scholar](#)

2.
  - Guldberg P.
  - Thor Straten P.
  - Birck A.
  - Ahrenkiel V.
  - Kirkin A.F.
  - Zeuthen J.

Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.

*Cancer Res.* 1997; 17: 3660-3663

[View in Article](#)

- [Google Scholar](#)

3.
  - Cairns P.
  - Okami K.
  - Halachmi S.
  - Halachmi N.
  - Esteller M.
  - Herman J.G.

Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

*Cancer Res.* 1997; 22: 4997-5000

[View in Article](#)

- [Google Scholar](#)
- 4. ◦ Rhei E.
- Kang L.
- Bogomolnyi F.
- Federici M.G.
- Borgen P.I.
- Boyd J.

Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

*Cancer Res.* 1997; 17: 3657-3659

[View in Article](#)

- [Google Scholar](#)
- 5. ◦ Kohno T.
- Takahashi M.
- Manda R.
- Yokota J.

Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers.

*Genes Chromosome Cancer.* 1998; 22: 152-156

[View in Article](#)

- [Scopus \(143\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)
- 6. ◦ Tashiro H.
- Blazes M.S.
- Wu R.
- Cho K.R.
- Bose S.
- Wang S.I.
- et al.

Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies.

*Cancer Res.* 1997; 18: 3935-3940

[View in Article](#)

- [Google Scholar](#)
- 7. ◦ Liaw D.
- Marsh D.J.
- Li J.
- Dahia P.L.
- Wang S.I.
- Zheng Z.
- et al.

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

*Nat Genet.* 1997; 11: 64-67

[View in Article](#)

- [Scopus \(1645\)](#)
- [Crossref](#)
- [Google Scholar](#)
- 8. ◦ Marsh D.J.
- Dahia P.L.
- Zheng Z.
- Liaw D.
- Parsons R.
- Gorlin R.J.
- et al.

Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

*Nat Genet.* 1997; 4: 333-334

[View in Article](#)

- [Scopus \(566\)](#)
- [Crossref](#)
- [Google Scholar](#)

9. ◦ Pilarski R.  
◦ Eng C.

will the real Cowden syndrome please stand up (again?) expanding mutational and clinical spectra of the PTEN hemartoma tumor syndrome.

*J Med Genet.* 2004; 41: 323-326

[View in Article](#)

- [Scopus \(250\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

10. ◦ Di Cristofano A.  
◦ Pesce B.  
◦ Cordon-Cardo C.  
◦ Pandolfi P.P.

Pten is essential for embryonic development and tumour suppression.

*Nat Genet.* 1998; 19: 348-355

[View in Article](#)

- [Scopus \(1270\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

11. ◦ Suzuki A.  
◦ de la Pompa J.L.  
◦ Stambolic V.  
◦ Elia A.J.  
◦ Sasaki T.  
◦ del Barco Barrantes I.  
◦ et al.

High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

*Curr Biol.* 1998; 22: 1169-1178

[View in Article](#)

- [Scopus \(686\)](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

12. ◦ Li J.  
◦ Yen C.  
◦ Liaw D.  
◦ Podsypanina K.  
◦ Bose S.  
◦ Wang S.I.  
◦ et al.

PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer.

*Science.* 1997; 275: 1943-1947

[View in Article](#)

- [Scopus \(4141\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

13.     ◦ Steck P.A.  
          ◦ Pershouse M.A.  
          ◦ Jasser S.A.  
          ◦ Yung W.K.  
          ◦ Lin H.  
          ◦ Ligon A.H.  
          ◦ et al.

Identification of a candidate tumor suppressor gene MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

*Natl Genet.* 1997; 15: 356-362

[View in Article](#)

- [Scopus \(2469\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

14.     ◦ Li D.M.  
          ◦ Sun H.

TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

*Cancer Res.* 1997; 11: 2124-2129

[View in Article](#)

- [Google Scholar](#)

15.     ◦ Maehama T.  
          ◦ Dixon J.E.

The tumor suppressor PTEN/MMAC1 dephosphorylates the lipid secondary messenger, phosphatidylinositol 3,4,5-triphosphate.

*J Biol Chem.* 1998; 273: 13375-13378

[View in Article](#)

- [Scopus \(2517\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

16.     ◦ Auger K.R.  
          ◦ Serunian L.A.  
          ◦ Soltoff S.P.  
          ◦ Libby P.  
          ◦ Cantley L.C.

PDGF dependent tyrosine phosphorylation stimulates production of novel polyphosphoinositides in intact cells.

*Cell.* 1989; 57: 167-175

[View in Article](#)

- [Scopus \(664\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text PDF](#)
- [Google Scholar](#)

17.     ◦ Myers M.P.  
          ◦ Pass I.  
          ◦ Batty I.H.  
          ◦ Van der Kaay J.  
          ◦ Stolarov J.P.  
          ◦ Hemmings B.A.  
          ◦ et al.

The lipid phosphatase activity of PTEN is critical for its tumor suppressor function.

*Proc Natl Acad Sci U S A.* 1998; 95: 13513-13518

[View in Article](#)

- [Scopus \(976\)](#)

- [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
18. ◦ Haas-Kogan D.  
◦ Shalev N.  
◦ Wong M.  
◦ Mills G.  
◦ Yount G.  
◦ Stokoe D.

Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN.

*Curr Biol.* 1998; 8: 1195-1198

[View in Article](#)

- [PubMed](#)
  - [Abstract](#)
  - [Full Text](#)
  - [Full Text PDF](#)
  - [Google Scholar](#)
19. ◦ Dudek H.  
◦ Datta S.R.  
◦ Franke T.F.  
◦ Birnbaum M.J.  
◦ Yao R.  
◦ Cooper G.M.  
◦ et al.

Regulation of neuronal survival by the serine-threonine protein kinase Akt.

*Science.* 1997; 275: 661-665

[View in Article](#)

- [Scopus \(2195\)](#)
  - [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
20. ◦ Datta S.R.  
◦ Dudek H.  
◦ Tao H.  
◦ Masters S.  
◦ Fu H.  
◦ Gotoh Y.  
◦ et al.

Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery.

*Cell.* 1997; 2: 231-241

[View in Article](#)

- [Scopus \(4864\)](#)
  - [Abstract](#)
  - [Full Text](#)
  - [Full Text PDF](#)
  - [Google Scholar](#)
21. ◦ Dan H.C.  
◦ Baldwin A.S.

Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt.

*J Immunol.* 2008; 11: 7582-7589

[View in Article](#)

- [Scopus \(60\)](#)
  - [Crossref](#)
  - [Google Scholar](#)
22. ◦ Downward J.



Ras signaling and apoptosis.

*Curr Opin Genet Dev.* 1998; 8: 49-54

[View in Article](#)

- [Scopus \(501\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

23. ◦ Ahmed N.N.  
◦ Grimes H.L.  
◦ Bellacosa A.  
◦ Chan T.O.  
◦ Tsichlis P.N.

Transduction of interleukin-2 antiapoptotic and proliferative signals via AKT protein kinase.

*Proc Natl Acad Sci U S A.* 1997; 94: 3627-3632

[View in Article](#)

- [Scopus \(486\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

24. ◦ Datta K.  
◦ Franke T.F.  
◦ Chan T.O.  
◦ Makris A.  
◦ Yang S.I.  
◦ Kaplan D.R.  
◦ et al.

AH/PH domain mediated interaction between AKT molecules and its potential role in AKT regulation.

*Mol Cell Biol.* 1995; 15: 2304-2310

[View in Article](#)

- [Scopus \(156\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

25. ◦ Brunet A.  
◦ Bonni A.  
◦ Zigmund M.J.  
◦ Lin M.Z.  
◦ Juo P.  
◦ Hu L.S.

AKT promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor.

*Cell.* 1999; 98: 857-868

[View in Article](#)

- [Scopus \(5236\)](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

26. ◦ Kennedy S.G.  
◦ Kandel E.S.  
◦ Cross T.K.  
◦ Hay N.

Akt/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria.

*Mol Cell Biol.* 1999; 19: 5800-5810

[View in Article](#)

- [Scopus \(576\)](#)

- [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
27. ◦ Brodt P.  
◦ Samani A.  
◦ Navab R.  
Inhibition of the type I insulin-like growth factor receptor expression and signaling: novel strategies for antimetastatic therapy.  
*Biochem Pharmacol.* 2000; 60: 1101-1107  
[View in Article](#)
- [Scopus \(93\)](#)
  - [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
28. ◦ Vivanco I.  
◦ Sawyers C.L.  
The phosphatidylinositol 3-kinase AKT pathway in human cancer.  
*Nat Rev Cancer.* 2002; 2: 489-501  
[View in Article](#)
- [Scopus \(4974\)](#)
  - [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
29. ◦ Jiang B.H.  
◦ Jiang G.  
◦ Zheng J.Z.  
◦ Lu Z.  
◦ Hunter T.  
◦ Vogt P.K.  
Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.  
*Cell Growth Differ.* 2001; 12: 363-369  
[View in Article](#)
- [PubMed](#)
  - [Google Scholar](#)
30. ◦ Ferlay J.  
◦ Shin H.R.  
◦ Bray F.  
◦ Forman D.  
◦ Mathers C.  
◦ Parkin D.M.  
Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008.  
*Int J Cancer.* June 17, 2010; (17 [Epub ahead of print])  
[View in Article](#)
- [Google Scholar](#)
31. ◦ Nalate R.B.  
◦ Zaretsky S.L.  
ZD1839 (Iressa): what's in it for the patients.  
*Oncologist.* 2002; 7: 25-30  
[View in Article](#)
- [PubMed](#)
  - [Google Scholar](#)
32. ◦ Woodhouse E.C.  
◦ Chuaqui R.F.  
◦ Liotta L.A.  
General mechanisms of metastasis.  
*Cancer.* 1997; 80: 1529-1537  
[View in Article](#)

- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

33. ◦ Myers M.P.  
 ◦ Stolarov J.P.  
 ◦ Eng C.  
 ◦ Li J.  
 ◦ Wang S.I.  
 ◦ Wigler M.H.  
 ◦ et al.

PTEN, the tumor suppressor from human chromosome10q23, is a dual-specificity phosphatase.  
*Proc Natl Acad Sci U S A.* 1997; 94: 9052-9057

[View in Article](#)

- [Scopus \(716\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

34. ◦ Blaskovich M.A.  
 ◦ Lin Q.  
 ◦ Delarue F.L.  
 ◦ Sun J.  
 ◦ Park H.S.  
 ◦ Coppola D.  
 ◦ et al.

A platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice.

*Nat Biotechnol.* 2000; 18: 1065-1070

[View in Article](#)

- [Scopus \(129\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

35. ◦ Roy B.C.  
 ◦ Kohno T.  
 ◦ Iwakawa R.  
 ◦ Moriguchi T.  
 ◦ Kiyono T.  
 ◦ Morishita K.  
 ◦ et al.

Involvement of LKB1 in epithelial-mesenchymal transition (EMT) of human lung cancer cells.

*Lung Cancer.* 2010; 70: 136-145

[View in Article](#)

- [Scopus \(73\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

36. ◦ Soria J.C.  
 ◦ Lee H.Y.  
 ◦ Lee J.I.  
 ◦ Wang L.  
 ◦ Issa J.P.  
 ◦ Kemp B.L.  
 ◦ et al.

Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation.

*Clin Cancer Res.* 2002 May; 8: 1178-1184

[View in Article](#)

- [PubMed](#)
  - [Google Scholar](#)
37. ◦ Noro R.  
◦ Gemma A.  
◦ Miyanaga A.  
◦ Kosaihira S.  
◦ Minegishi Y.  
◦ Nara M.

PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.

*Int J Oncol.* 2007; 31: 1157-1163

[View in Article](#)

- [PubMed](#)
  - [Google Scholar](#)
38. ◦ Ozes O.N.  
◦ Akca H.  
◦ Mayo L.D.  
◦ Gustin J.A.  
◦ Maehama T.  
◦ Dixon J.E.  
◦ et al.

Phosphatidylinositol 3-kinase/AKT/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

*Proc Natl Acad Sci U S A.* 2001; 98: 4640-4645

[View in Article](#)

- [Scopus \(318\)](#)
  - [PubMed](#)
  - [Crossref](#)
  - [Google Scholar](#)
39. ◦ Greenlee R.T.  
◦ Hill-Harmon M.B.  
◦ Murray T.  
◦ Thun M.

Cancer statistics.

*CA Cancer J Clin.* 2001; 51: 16-36

[View in Article](#)

- [Scopus \(3287\)](#)
  - [Crossref](#)
  - [Google Scholar](#)
40. ◦ Tang J.M.  
◦ He Q.Y.  
◦ Guo R.X.  
◦ Chang X.J.

Phosphorylated AKT overexpression and loss of PTEN expression in non-small lung cancer confers poor prognosis.

*Lung Cancer.* 2006; 51: 181-191

[View in Article](#)

- [Scopus \(312\)](#)
  - [PubMed](#)
  - [Abstract](#)
  - [Full Text](#)
  - [Full Text PDF](#)
  - [Google Scholar](#)
41. ◦ Marsit C.J.  
◦ Zheng S.  
◦ Aldape K.

- Hinds P.W.
- Nelson H.H.
- Wiencke J.K.
- et al.

PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics allelic loss, and epigenetic alteration.

*Human Pathol.* 2005; 36: 768-776

[View in Article](#)

- [Scopus \(212\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

42. ◦ Akca H.  
 ◦ Tani M.  
 ◦ Hishida T.  
 ◦ Matsumoto S.  
 ◦ Yokota J.

Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.

*Lung Cancer.* 2006; 54: 25-33

[View in Article](#)

- [Scopus \(41\)](#)
- [PubMed](#)
- [Abstract](#)
- [Full Text](#)
- [Full Text PDF](#)
- [Google Scholar](#)

43. ◦ Furnari F.B.  
 ◦ Lin H.  
 ◦ Huang H.S.  
 ◦ Cavenee W.K.

Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain.

*Proc Natl Acad Sci U S A.* 1997; 94: 12479-12484

[View in Article](#)

- [Scopus \(379\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

44. ◦ Nakanishi K.  
 ◦ Sakamoto M.  
 ◦ Yasuda J.  
 ◦ Takamura M.  
 ◦ Fujita N.  
 ◦ Tsuruo T.  
 ◦ et al.

Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer.

*Cancer Res.* 2002; 10: 2971-2975

[View in Article](#)

- [Google Scholar](#)

45. ◦ Lobo G.P.  
 ◦ Waite K.A.  
 ◦ Planchon S.M.  
 ◦ Romigh T.  
 ◦ Nassif N.T.

- Eng C.

Germline and somatic cancer-associated mutations in the ATP-binding motifs of PTEN influence its subcellular localization and tumor suppressive function.

*Hum Mol Genet.* 2009; 15: 2851-2862

[View in Article](#)

- [Scopus \(36\)](#)
- [Crossref](#)
- [Google Scholar](#)

46. ◦ Heering J.
- Erlmann P.
- Olayioye M.A.

Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.

*Exp Cell Res.* 2009; 315: 2505-2514

[View in Article](#)

- [Scopus \(34\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

47. ◦ Maier D.
- Jones G.
- Li X.
- Schönthal A.H.
- Gratzl O.
- Van Meir E.G.
- et al.

The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells.

*Cancer Res.* 1999; 59: 5479-5482

[View in Article](#)

- [PubMed](#)
- [Google Scholar](#)

48. ◦ Bowen K.A.
- Doan H.Q.
- Zhou B.P.
- Wang Q.
- Zhou Y.
- Rychahou P.G.
- et al.

PTEN loss induces epithelial–mesenchymal transition in human colon cancer cells.

*Anticancer Res.* 2009; 11: 4439-4449

[View in Article](#)

- [Google Scholar](#)

49. ◦ Shukla S.
- Maclennan G.T.
- Hartman D.J.
- Fu P.
- Resnick M.I.
- Gupta S.

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.

*Int J Cancer.* 2007; 121: 1424-1432

[View in Article](#)

- [Scopus \(252\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

50. ◦ Zhang J.G.
- Wang J.J.
- Zhao F.

- Liu Q.
- Jiang K.
- Yang G.H.

MicroRNA-21 represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC).

*Clin Chim Acta.* 2010; 411: 846-852

[View in Article](#)

- [Scopus \(452\)](#)
- [PubMed](#)
- [Crossref](#)
- [Google Scholar](#)

## Article Info

### Publication History

Published online: February 21, 2011

Accepted: January 18, 2011

Received in revised form: January 11, 2011

Received: October 1, 2010

### Identification

DOI: <https://doi.org/10.1016/j.lungcan.2011.01.012>

### Copyright

© 2011 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.

### ScienceDirect

[Access this article on ScienceDirect](#)

## Linked Article

- [Erratum to “Invasiveness and anchorage independent growth ability augmented by PTEN inactivation through the PI3K/AKT/NFκB pathway in lung cancer cells” \[Lung Cancer 73 \(3\) \(2011\) 302–309\]](#)  
*Lung Cancer* Vol. 101
  - [Preview](#)  
The publisher regrets that the authors mistakenly inserted the incorrect GAPDH line on Fig. 2A. All densitometric analyses and values were calculated correctly with using correct GAPDH line in previously figure too. Mistake was just put wrong GAPDH on figure. A corrected Fig. 2A with the correct GAPDH line is now below.
  - [Full-Text](#)
  - [PDF](#)

## Related Articles

[Hide CaptionDownloadSee figure in Article](#)  
[Toggle Thumbstrip](#)

- [Download Hi-res image](#)

- [Download .PPT](#)



[Home](#)

## **ARTICLES AND ISSUES**

[Articles in Press](#)

[Current Issue](#)

[List of Issues](#)

## **FOR AUTHORS**

[About Open Access](#)

[Author Information](#)

[Permissions](#)

[Researcher Academy](#)

[Submit a Manuscript](#)

## **JOURNAL INFO**

[About Open Access](#)

[About the Journal](#)

[Abstracting/Indexing](#)

[Advertising Information](#)

[Career Opportunities](#)

[Contact Information](#)



[Editorial Board](#)

[Pricing](#)

[New Content Alerts](#)

**SUBSCRIBE**

**SOCIETY INFO**

[International Lung Cancer Consortium \(ILCCO\)](#)

[European Thoracic Oncology Platform \(ETOP\)](#)

[British Thoracic Oncology Group \(BTOG\)](#)

**MORE PERIODICALS**

[Find a Periodical](#)

[Go to Product Catalog](#)

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie Preference Center](#) for this site.

Copyright © 2022 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.

- [Privacy Policy](#)
- [Terms and Conditions](#)
- [Accessibility](#)
- [Help & Contact](#)

